 | | Vol. 12.02 – 21 January, 2021 |
| |
|
|
| Investigators describe a tissue-engineered model that reproduces bone tissue complexity and bone remodeling processes with high fidelity and control. An osteoid-inspired biomaterial—demineralized bone paper—directs osteoblasts to deposit structural mineralized bone tissue and subsequently acquire the resting-state bone lining cell phenotype.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated that their integrated hybrid additive manufacturing platform offers the ability to create scaffolds with continuous physicochemical gradients, and to selectively activate or coat the scaffold surfaces.
[Nature Communications] |
|
|
|
| The authors report a generalizable strategy utilizing a photomediated oxime ligation to covalently decorate naturally derived hydrogels with bioactive proteins including growth factors.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists recruited 33 lung cancer patients with brain oligo-metastasis to explore the genomic features and tumor immune microenvironment of the lung and brain metastasis independently.
[Cell Death & Disease] |
|
|
|
| Flow cytometric analyses indicated that induction of epithelial-mesenchymal transition decreased trastuzumab binding, prior to overt loss of HER2 expression in trastuzumab-emtansine-resistant (TDM1R) cells. Kinome analyses of TDM1R cells indicated increased phosphorylation of ErbB1, ErbB4, and FGFR1.
[npj Breast Cancer] |
|
|
|
| Researchers report that eukaryotic protein translation elongation factor 1α2 (EEF1A2) mediates the epithelial-mesenchymal transformation, to promote the metastasis of lung adenocarcinoma cells in vitro and in vivo.
[British Journal of Cancer] |
|
|
|
| Investigators hypothesized that localized presentation of transforming growth factor-β1 and bone morphogenetic protein-2 to engineered human mesenchymal stem cell tubes mimicking femoral diaphyses induces endochondral ossification.
[Communications Biology] |
|
|
|
| Scientists found that combined therapy with asiatic acid, a Smad7 agonist, and naringenin, a Smad3 inhibitor, effectively retrieved the balance between Smad3 and Smad7 signaling in the TGF-β-rich tumor microenvironment and thus significantly suppressed tumor invasion and metastasis in mouse models of melanoma and lung carcinoma.
[Molecular Therapy-Oncolytics] |
|
|
|
| The authors demonstrated a robust and simple approach to form collagen substrates with different topographies by evaporating droplets of a collagen solution.
[Scientific Reports] |
|
|
|
| Scientists evaluated whether esophageal cancer cell acquisition of stronger malignant characteristics and refractoriness to chemoradiotherapy were mediated by cancer-associated fibroblasts.
[Scientific Reports] |
|
|
|
| Researchers investigated whole neurogenic bladder’s progression changes, as well as the expression of TGF-β1 fibrosis pathway-related proteins in bilateral spinal nerve-amputated juvenile rats.
[Pediatric Research] |
|
|
|
|
| The authors detail recent advances in our understanding of the functions of TGF-β superfamily members and their corresponding receptors, signaling pathways, and downstream molecular targets in regulating human extravillous trophoblasts invasion from studies using various in vitro or ex vivo experimental models.
[Trends in Endocrinology and Metabolism] |
|
|
|
|
| Organogenesis Holdings Inc. announced that the first patient has been enrolled in its pivotal Phase III clinical trial evaluating the safety and efficacy of ReNu®, a cryopreserved amniotic suspension allograft, for the management of symptoms associated with knee osteoarthritis. ReNu consists of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and ECM components.
[Organogenesis, Inc.] |
|
|
|
| The US FDA has notified Histogen Inc. that it has additional questions about their Investigational New Drug application package for the planned Phase I/II clinical trial of HST-003, which is intended to evaluate the safety and efficacy of human ECM implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.
[Histogen, Inc.] |
|
|
|
|
| February 17 – 21, 2021
Virtual |
|
|
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Rutgers Cancer Institute of New Jersey – Rutgers, New Jersey, United States |
|
|
|
| | STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| | Institute of Pharmacology and Structural Biology – Toulouse, France |
|
|
|
| | University of Florida – Gainesville, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
